

## DAFTAR PUSTAKA

1. Kellum J, Aspelin P, Barsoum R. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Guidline for Acute Kidney Injury. *Kidney Inter, Suppl.* 2012; 2: p. 76 – 86
2. Lacquaniti A, Buemi F, Lupica R, Giardina C, Mure G, Arena A, et al. Can Neutrophil Gelatinase-Associated Lipocalin Help Depict Early Contrast Material-Induced Nephropathy? *Radiology.* 2013 April; 267.
3. Eng J, wilson r, Zhang A, sherrod c, hutflless s, Bass e. Comparative effect of contrast media type on the incidence of contrast-induced nephropathy a systematic review and meta-analysis. *annals of internal medicine.* 2016 march; 164.
4. Kooiman J, Pasha S, Zondag W, Sljpkens Y, Vander MA, Huisman M. Meta-analysis: Serum creatinine changes Following contrast enhanced CT imaging. *Eur J Radiol.* 2012; 81: p. 2554–61.
5. Peer S, Choh NA, Gojwari TA. Incidence of Contrast-induced nephropathy a prospective study. *Journal of Renal Injury Prevention.* 2016 November; 3: p. 192–8.
6. Mehran R, Aymong e, Nikolsky E, Lasic Z. A Simple Risk Score for Prediction of contrast -Induced Nephropathy After Percutaneous Coronary Intervention. *Interventional Cardiology.* 2004 june; 44.
7. Banda J, Duarte R, Dickens C, Peek D, Muteba M, Paget G. Risk factors and outcomes of contrast-induced. *Samj Reseachr.* 2016 July; 106.

8. fahling M, Seeliger E, Patzak A, Persson P. Understanding and preventing contrast-induced acute kidney injury. *Nephrology*. 2017 jan.
9. Filiopoulos V, Biblaki D, Vlassopoulos D. Neutrophil Gelatinase-Associated Lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography. *Renal Failure*. 2014 March; 36: p. 979–86.
- 10 Vanmassenhove J, Vanholder R, Nagler E, Van BW. Urinary and serum Biomarker for the diagnosis of Acute Kidney Injury: asystemic review. *Kidney Int*. 2013;; p. 1008–16.
- 11 Singer E, Marko L, Paragus N, Barasch J, Dragun D, Muller DN, et al. Neutrophil Gelatinase-associated lipocalin: pathophysiology and clinical applications. *Acta Physiologica*. 2013 november;; p. 663–72.
- 12 Tong J, Li H, Zhang H, Luo Z, Huang Y, Huang J. Neutrophil Gelatinase-Associated Lipocalin in the Prediction of Contrast-Induced Nephropathy : A ssystemic Review and Meta-analysis. *J Cardiovasc Pharmacol*. 2015 september; 66: p. 239–45.
- 13 Kafkas N, Liakos C, Zoubouloglou F, Dagadaki O, Dragasis S, Makris K. Neutrophil Gelatinase-Associated Lipocalin as an early Marker of Contrast-Induced Nephropathy After Elective Invasive Cardiac Procedures. *Clin.Cardiol*. 2016 January.
- 14 Yuniadi Y, Ningrum NR. Risk factors and incidence of contrast induced nephropathy following coronary intervention. *Nephropathy after coronary intervention*. 2008 June; 17.
- 15 Davidson C, Stacul F, McCullough P. Contrast Medium Use. *Am J Cardiol*. 2006;; p. 42k–58k.

- 16 Gleeson T, Bulugahapitiya S. Contrast-Induced Nephropathy. *American Journal of Roentgenology*. 2004; 183: p. 1673–89.
- 17 Rudnick M, Kesselheim A, Goldfarb S. Contrast-Induced Nephropathy: How it develops, How to prevent it. *Cleveland Clinical Journal of Medicine*. 2006; 73: p. 75–78.
- 18 Mehran R, Aymon E, Nikolsky E. Simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. *J Am Coll Cardiol*. 2004; 44: p. 1393–9.
- 19 Sudarsky D, Nikolsky E. Contrast Induced Nephropathy in Interventional Cardiology. *International Journal of Nephrology and Renovascular Disease*. 2011; 4: p. 85–99.
- 20 Aspelin P, Aubry P, Fransson S, Strasser R, Wilenbrock R. Nephrotoxicity in High-Risk Patients Study of Iso-osmolar and Low Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in High-risk patients undergoing angiography. *N Engl J Med*. 2003; 348: p. 491–9.
- 21 Jo S, Youn T, Park J, Koo B, Kang H. Iodixanol is less nephrotoxic than ioxaglate in patients with renal insufficiency after coronary angiography. *J Am Coll Cardiol*. 2005; 45.
- 22 Lerma E, Berns J, Nissensohn A. *CURRENT Diagnosis & Treatment : Nephrology & Hypertension*; 2012.
- 23 Wong P, Chambers C, Davidson C. Pathophysiology of contrast-induced Nephropathy. *International Journal of Cardiology*. 2011; 69: p. 135–40.
- 24 Wong G, Irwin M. Contrast-induced nephropathy. *Br J Anaesth*. 2007 Oct; 4: p. 474–83.

- 25 Rudnick M, Tumlin J. Pathogenesis, Clinical features, and diagnosis of contrast-induced nephropaty. Up to date. 2012 Sept.
- 26 Roesli RMA. Diagnosis dan Pengelolaan Gangguan Ginjal Akut. kedua ed. Jakarta; 2011.
- 27 Kellum J, Bellomo R, Ronco C. The Concept of acute kidney injury and the RIFLE Criteria In acute kidney Injury. 2007;; p. 10–16.
- 28 Derajavan P, Parikh C. Biomarkers of Acute Kidney Injury: Can we replace Serum Creatinin? Clinical Nephrology. 2007;; p. 269–78.
- 29 Moltoris B, Melnikov V, Okusa M. Technology Insight; Biomarker Development in acute Kidney Injury.What can We Anticipate Nephrology. 2008; 4: p. 154–65.
- 30 Adiyanti Ss, Loho T. Acute Kidney Injury (AKI) Biomarker. Acta Med Indones Journal Intern Med. 2012 July; 44: p. 246–55.
- 31 Chakraborty S, Kaur St, Batra S, Guha S. Neutrophil Gelatinase Associated Lipocalin: structure, Fungtion and role in Human Pathogenesis. 2011.
- 32 Haase M. NGAL to predict acute kidney injury-potential application and limitation. 2010.
- 33 Sachin S, Dinna C, Ilona B, Chang Y, Federico N, Paolo L. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 2010;; p. 141–50.
- 34 M.Schimidt O, Kiyoshi M, JauYi L, Avtandil K, David JC, Prasad D. Dual Action of Neutrophil Gelatinase-Associated Lipocalin. J Am Soc Nephrol. 2007;; p. 407–13.

- 35 Davide B, Valentina D, Giuseppe C, Susana C, ANtoine B, Antonio L. Neutrophil Gelatinase-associated Lipocalin (NGAL) as a marker of kidney damage. *Am J Kidney Dis*. 2008.
- 36 M.Schimidt O. Neutrophil Gelatinase associated lipocalin as a biomarker of acute kidney injury -where do we stand today?. *Nephrol Dial Transplant*. 2011.
- 37 Linjun C, jenny R, Wenyu H, Per V, Shengyuan X. The origin of multiple molecular forms in urine of HNL/NGAL. *Clin J Am Soc Nephrol*. 2010.
- 38 Soni S, Cruz D, Bobek I, Chionh C, Naleso F, Lentini P. NGAL; A biomarker of acute Kidney Injury and other Systemic Conditions. *Int Urol Nephrol*. 2010;; p. 141–50.
- 39 Devarajan P. Neutrophil Gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomark Med*. 2010;; p. 265–80.
- 40 Hirsch R, dent C, Pfriem H. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. *Pediatr Nephrol*. 2007; 22: p. 2089–95.
- 41 Ling W, Zhaohui N, Ben H. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. *Nephron Clin Pract*. 2008; 108: p. 176–81.
- 42 Shaker O, El-shehaby A, El-khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. *Angiology*. 2010; 61: p. 731–6.
- 43 Haase M, Bellomo R, Devarajan P, Schlattman P, Haase-Fielitz A. The NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-

- associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systemic review and meta-analysis. *AM j Kidney Dis.* 2009; 54: p. 1012–24.
- 44 Constantin J , Futier E, Roszyk L, Perbet S, Sapin V, Lautrette A. Plasma Neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury. *Ann InternMed.* 2008.
- 45 Clerico A, Galli C, Fortuna A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. *Clin Chem Lab Med.* 2012.
- 46 Schmidt-ott. neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury-where do we stand today. *nephrol dial transplant.* 2011.
- 47 Ridder W, De Geus H. Neutrophil Gelatinase-associated lipocalin as an early indicator for mortality in adult critically ill patients with acute kidney injury. *Rotterdam Critical Care.* 2010.
- 48 Bangert K, Uttenthal L. Urinary and plasma NGAL levels reflect the severity of acute kidney injury. *Denmark Critical Care.* 2010.
- 49 Nisi K. Predictive ability of NGAL as marker of renal damage: evaluation of multiple clinical setting. *Universita di Bologna.* 2012.
- 50 Sweiger M, Chambers C, Davidson C. Prevention of contrast induced nephropathy: recommendations for the high risk patients undergoing cardiovascular procedures. *Cath and Cardiovasc Interv.* 2007; 69: p. 135–40.
- 51 Shylaja TV, Amit Sonagra, Asmabi Makandar, Patnaik, Shanthinaidu, Serum Neutrophil gelatinase-associated lipocalin as an early biomarker of acute kidney injury in subjects undergoing percutaneous transluminal coronary

angiogram with normal EGFR. Original Research Article, september 2017.

- 52 Maria J, Perez-Vizcayno, Rosa A, Hernandez-Atolin, Fernando Alfonso, Changes in Percutaneous Coronary Intervention over the last 20 years: Demographic, Epidemiologic and Clinical characteristic, techniques, and outcomes. Original Article, August 2006.
- 53 Nikolsky E, Mehran R, Turcot D, dkk. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. *Am J Cardiol.* 2004;94(3):300–5.
- 54 Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. *Am J Med.* 1990;89(5):615–20.
- 55 Peer S, Nasser ahmad choh, Tariq ahmad gojwari, Incidence of contrast-induced nephropathy a prospective study. *Journal of renal injury prevention,* November 2016.
- 56 Otto G, jorge, Ha-yeun chung, kristin knoll, thomas neumann, Plasma Neutrophil Gelatinase-associated lipocalin is primarily related to inflammation during sepsis: a translational Approach. *Plos One,* March 2015.
- 57 Moon J, yeong-min lim, kim sang hoon, woo-in yang, serial measurements of neutrophil gelatinase-associated lipocalin (NGAL): prognostic value in STEMI patients treated by primary percutaneous coronary intervention. *ACC.12,* March 2017
- 58 Nusca A, Marco Miglionico, Claudio proscia, Laura Ragni, massimiliano carassiti, Early prediction contrast induced acute kidney injury by a "bedside" assessment of neutrophil gelatinase associated lipocalin during elective percutaneous coronary intervention. *Plos one,* March 2018.
- 59 Gajewska-B, J Malyszko, Sitniewska, Dobrzycki, Neutrophil gelatinase

associated lipocalin and renal function after percutaneous coronary intervention. *Amj*, April 2006

- 60 Briguori, A. Colombo, F. Airoidi et al., “Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures,” *Catheterization and Cardiovascular Interventions*, vol. 67, no. 2, pp. 175–180, 2006.

